ICER Lowballs Critical Alzheimer’s Medications

February 2, 2023

ICER’s cost-effectiveness analysis doesn’t wholly depict
the value of new Alzheimer’s medications.

Read One-Pager

Categorized in: Analysis

Previous Post ►